法官驳回将Infowars出售给洋葱新闻网:需知信息 Latest News

法官驳回将Infowars出售给洋葱新闻网:需知信息

(SeaPRwire) - 周二晚上,一位联邦法官驳回了将亚历克斯·琼斯的Infowars出售给讽刺新闻媒体The Onion的拍卖,批评拍卖流程存在缺陷,以及2012年桑迪胡克小学枪击案受害者家属将获得的金额。 11月14日,The Onion在与琼斯相关的一家公司中胜出,成为竞标者。琼斯的阴谋论平台因法院下令他支付近15亿美元的赔偿金而被拍卖,这些赔偿金源于他将美国历史上最致命的学校枪击案之一称为骗局。 休斯顿的美国破产法官克里斯托弗·洛佩兹决定不批准此次出售,这意味着琼斯可以继续留在他在德克萨斯州奥斯汀的Infowars总部。The Onion 原计划在1月份将琼斯赶走,并将Infowars重新定位为一个恶搞节目。 “我们对今天的裁决深感失望,但The Onion 将继续寻求解决方案,帮助桑迪胡克的家庭为他们所遭受的恐怖获得积极的结果,”The Onion母公司Global Tetrahedron的首席执行官本·柯林斯周二晚些时候在社交媒体上发帖。 洛佩兹指出了拍卖流程中存在的问题——但没有不当行为。他说他不希望再次进行拍卖,并将决定下一步行动的任务留给了负责监督拍卖的受托人。 The Onion 在拍卖中为Infowars的资产提供了175万美元的现金和其他奖励。经营琼斯名下销售营养补充剂网站的第一联合美国公司(First United American Companies)出价350万美元。 这些出价只是琼斯被康涅狄格州和德克萨斯州桑迪胡克枪击案受害者家属提起的诽谤诉讼中被判赔付金额的一小部分。洛佩兹表示,拍卖结果“为家属们留下了很多钱”。 “你必须努力争取,为他们争取你能得到的一切,”洛佩兹说。 在康涅狄格州起诉琼斯的桑迪胡克家属的律师克里斯托弗·马泰伊表示,他们对法官的裁决感到失望。 马泰伊在一份声明中说:“这些家庭已经克服了无数的延误和障碍,他们仍然像以往一样坚韧和坚定,决心让亚历克斯·琼斯及其腐败的企业为其造成的损害负责。“这个决定并没有改变这样一个事实,那就是亚历克斯·琼斯很快就会开始偿还对这些家庭的债务,并且只要需要,他就会继续这样做。” 琼斯没有出席诉讼程序,他很快回到节目中,为法官的决定喝彩。 “我们可以庆祝法官在人类历史上最荒谬、最欺诈的拍卖中做出了正确的事情,”他说。 尽管The Onion的现金出价低于第一联合美国公司,但它还包括许多桑迪胡克家庭承诺放弃75万美元的拍卖收益,并将其捐赠给其他债权人,这使得其他债权人获得的资金比第一联合美国公司的出价所能提供的更多。 亚历克斯·琼斯的破产案 Infowars的出售是琼斯个人破产案的一部分,他在2022年末被命令赔偿康涅狄格州和德克萨斯州桑迪胡克枪击案受害者家属近15亿美元的诽谤赔偿金后提出申请。 琼斯多次称导致20名儿童和6名教师丧生的枪击事件是演员们策划的骗局,目的是加强枪支管制。许多受害者的父母和孩子在法庭上作证说,他们受到了琼斯的阴谋论及其追随者的威胁的创伤。 琼斯此后承认康涅狄格州的学校枪击事件确实发生了。 Infowars出售的大部分收益以及琼斯的许多个人资产将归桑迪胡克的家庭所有。部分收益将归琼斯的其他债权人所有。 拍卖监督人为自己做出的决定辩护 受托人克里斯托弗·默里在休斯顿为期两天的冗长听证会上为The Onion的出价进行了辩护,作证说他不偏袒任何一方竞标者,也没有偏见。 他还透露,第一联合美国公司(First United American Companies)最近几天提交了一份修改后的出价,但他表示他无法接受,因为康涅狄格州诉讼中的桑迪胡克家庭对此表示反对。 The Onion将其出价(包括桑迪胡克家庭的提议)估值为700万美元,因为这个金额等于一个能为其他债权人提供相同金额的购买价格。 默里的律师在上个月提交的法庭文件中称,第一联合美国公司(First United American Companies)要求取消The Onion出价的要求是“一个失望的竞标者试图影响一个本来公平公开的选举过程的不当行为”。 琼斯的律师本·布鲁克斯指出,桑迪胡克的诉讼判决可能会在待决的上诉中被推翻,并让默里承认,如果这种情况发生,The Onion出价中桑迪胡克家庭的提议可能会破裂。这是因为他们有权获得的拍卖收益的比例可能会急剧下降,他们将无法获得75万美元的出售收益来支付给其他债权人。 拍卖师杰夫·塔嫩鲍姆在周一为出价的价值及其选择进行了辩护。 将Infowars拍卖 拍卖的物品包括奥斯汀Infowars工作室的所有设备和其他资产,以及其社交媒体账户、网站、视频档案和产品商标的权利。琼斯使用该工作室在其Infowars网站、X社交平台账户和广播电台上播放他的极右翼、充满阴谋论的节目。琼斯的许多个人资产也被出售。 如果The Onion获得批准收购Infowars并将琼斯赶走,琼斯已经建立了另一个工作室、网站和社交媒体账户。琼斯曾表示,如果拍卖赢家对他友好,他可以继续使用Infowars平台。 琼斯正在上诉被判支付的赔偿金,理由是言论自由权。本文由第三方内容提供商提供。SeaPRwire (https://www.seaprwire.com/)对此不作任何保证或陈述。 分类: 头条新闻,日常新闻 SeaPRwire为公司和机构提供全球新闻稿发布,覆盖超过6,500个媒体库、86,000名编辑和记者,以及350万以上终端桌面和手机App。SeaPRwire支持英、日、德、韩、法、俄、印尼、马来、越南、中文等多种语言新闻稿发布。
More
住房为何是应对气候变化的第一道防线
“` Latest News

住房为何是应对气候变化的第一道防线 “`

(SeaPRwire) - 气候变化正在重塑世界,加剧了全球在健康、就业、教育和人身安全方面的挑战。然而,世界各国领导人往往忽视了气候危机最直接影响人们的地方:他们的住房。 日益严重的自然灾害、海平面上升和极端天气事件不仅威胁着现有的房屋,也推高了建造和维护安全、体面住房的成本。通过在70多个国家开展的工作,Habitat for Humanity亲眼目睹了低收入家庭(尽管他们对全球碳排放的贡献最小)如何承受气候变化的冲击。对于居住在贫民窟和其他非正规住区超过10亿人来说,这种情况尤其如此。 但好消息是:如果我们愿意真正倾听,了解气候变化如何影响他们的日常生活,并投资于大规模努力,使更多房屋安全、健康和具有韧性,那么这些相同的社区就掌握着解决方案。 利害关系再严重不过了。到2050年,气候迁移可能导致全球约有 人流离失所,低收入和快速城市化的国家将受到最大的影响。与大多数受气候影响的社区将迁移到高收入国家的担忧相反,大多数人仍然留在本国境内,许多人居住在非正规住区的简陋房屋中。这些地区已经容易受到气候变化的影响,随着流离失所者的涌入,这些地区将面临更大的压力,给有限的资源带来巨大的压力。 无论我们是否意识到,我们称之为家的地方是气候危机的核心——既是造成问题的原因,又具有减轻气候变化影响的巨大潜力。根据联合国环境规划署的数据,建筑环境占全球温室气体排放量的21%,其中住宅建筑占总排放量的17%。随着地球变暖和气候灾害加剧,住房的作用变得更加关键——不仅在于减少排放,还在于为受影响最严重的群体提供稳定和安全。 世界各国领导人有机会——我认为也有义务——关注气候迁移,尤其是在全球南方。对这一因素视而不见,就等于忽略了解决气候挑战以及经济发展、健康和教育等关键问题的一个重要部分。 韧性住房与发展 大量研究证明,拥有一个安全可靠的家园能够提高生活质量的许多可衡量结果。即使是最简单的住所也能极大地影响居住者生活轨迹。然而,对于居住在非正规住区的数百万家庭来说,房屋往往缺乏基本服务、土地产权安全和气候韧性。这些挑战令人畏惧,但也为应对气候变化提供了独特的机会。通过投资于非正规住区居民的充分住房,我们不仅能够满足道德责任,还能开启建设可持续和公平未来的最明智和最有效战略之一。 代表Habitat for Humanity进行的研究表明,足够的住房是福祉和可持续性的强大催化剂。它会影响非正规住区居民和更广泛社会的国家经济发展、收入、健康和教育。如果大规模升级非正规住区的住房,一些国家的GDP和人均收入可能会增加多达10.5%,多达4160万额外儿童可以入学。 虽然住房与气候变化之间的联系很明确,但世界各国领导人仍在忽视获得充分住房作为适应和减缓工具。 气候行动计划中的关键差距 国家自主贡献(NDC)是全球气候行动的基石,它阐述了每个国家根据《巴黎协定》减少碳排放和适应气候变化影响的承诺。然而,所有国家中,只有 在其NDC中对住房部门表示高度承诺,而超过 的国家根本没有优先考虑住房。 这种遗漏是一个明显的疏忽。以住房为中心的方法,使社区和家庭适应气候变化的影响(包括全面的贫民窟升级),对于气候行动和推进可持续发展目标至关重要。这些战略不仅能够应对气候韧性问题,还能为改善健康、教育和经济成果提供途径。 为了应对这些挑战,Habitat for Humanity调整了我们的工作方式。在世界各地,Habitat建造和翻新房屋,增加可持续自然资源和建筑实践的使用,同时减少房屋整个生命周期中的温室气体排放。 为了扩大这些努力,我们敦促七国集团领导人在其气候行动中认识并支持住房减缓和适应,尤其是在非正规住区。通过投资于住房解决方案,各国可以在实现其气候目标的同时,促进更具韧性、可持续和公平的社区。 家不仅仅是居住的地方。家意味着更好的健康、安全和保障,是家庭和地球更好未来的基础。本文由第三方内容提供商提供。SeaPRwire (https://www.seaprwire.com/)对此不作任何保证或陈述。 分类: 头条新闻,日常新闻 SeaPRwire为公司和机构提供全球新闻稿发布,覆盖超过6,500个媒体库、86,000名编辑和记者,以及350万以上终端桌面和手机App。SeaPRwire支持英、日、德、韩、法、俄、印尼、马来、越南、中文等多种语言新闻稿发布。
More
司法部在查封记者电话记录时忽视了相关政策:监督报告 Latest News

司法部在查封记者电话记录时忽视了相关政策:监督报告

(SeaPRwire) - 华盛顿——根据一份即将发布的监察长报告,在特朗普政府执政期间,联邦检察官在对媒体泄密进行调查时,搜查记者电话记录的过程中,绕过了司法部的一些规定。而这种积极追捕记者消息来源的做法可能会再次出现。 司法部检察长办公室周二发布的这份报告还发现,一些国会工作人员的记录也被检察官获取,仅仅是因为他们接触了机密信息,尽管这是他们工作职责的一部分。其中,获得记录的人包括总统当选人特朗普提名的联邦调查局局长人选,他当时是众议院情报委员会的工作人员。帕特尔去年在对该部门的诉讼中表示,谷歌通知他,该部门已对他发出传票。 尽管这份报告记述的是几年前司法部的行为,但此事具有新的意义,因为帕特尔已经表达了他“追捕”那些“对美国公民撒谎”的媒体成员的愿望,以及他认为联邦政府应该清除反对特朗普的“阴谋者”。 这些言论增加了这样一种可能性:在新的领导下,司法部——特朗普已挑选佛罗里达州前司法部长担任他的司法部长——可能会撤销一项规定,该规定(除有限例外情况外)禁止检察官在对敏感信息泄露进行调查时秘密查封记者的电话记录。 2021年,总检察长采取的行动是在有关司法部在特朗普政府期间获取《华盛顿邮报》、《美国有线电视新闻网》和《纽约时报》记者记录的披露引发强烈抗议之后做出的,这些记录是关于谁泄露了与调查俄罗斯干涉大选和其他国家安全事务相关的政府机密的调查。 监察长发现,司法部在2020年寻求记者记录时,没有遵守几年后才实施的某些部门规定,包括让新闻媒体审查委员会审查请求。该委员会旨在确保除检察官以外的其他官员,包括该部门公共事务办公室负责人,能够对这种努力进行权衡。 根据报告,当时授权从美国有线电视新闻网、《纽约时报》和《华盛顿邮报》获取记录的总检察长,并没有明确批准使用寻求的不披露协议——这是部门政策所要求的。 司法部还查封了民主党众议员和时任众议员以及通过苹果公司从时任白宫法律顾问唐·麦加恩那里获得的数据,这些数据与俄罗斯调查有关的泄密事件有关。 根据报告,该部门追查了两名国会议员和43名国会工作人员的记录。监察长没有发现证据表明发起这些请求的职业检察官存在“报复性或政治动机”。根据报告,在大多数情况下,这些工作人员仅仅是因为他们作为工作职责的一部分接触机密材料的时间与包含秘密信息的新闻报道发表时间非常接近,才被视为嫌疑人。 加兰德的新政策列出了司法部仍然可以获取记者记录的几种情况,包括如果记者涉嫌为外国势力或恐怖组织工作;如果他们因不相关的活动而受到调查;或者如果他们通过犯罪手段(如非法闯入)获得了信息。 在民主党和共和党领导下,司法部都在努力平衡其保护新闻自由的决心和保护国家安全秘密的决心。 总统的第一任司法部长在对被视为积极侵犯新闻自由的行为(包括秘密查封美联社记者和编辑的电话记录)强烈抗议后,宣布了修订后的泄密调查指南。 而特朗普的第一任司法部长在俄罗斯干涉大选调查期间发生一系列披露事件后,于2017年宣布开展打击泄密行动。本文由第三方内容提供商提供。SeaPRwire (https://www.seaprwire.com/)对此不作任何保证或陈述。 分类: 头条新闻,日常新闻 SeaPRwire为公司和机构提供全球新闻稿发布,覆盖超过6,500个媒体库、86,000名编辑和记者,以及350万以上终端桌面和手机App。SeaPRwire支持英、日、德、韩、法、俄、印尼、马来、越南、中文等多种语言新闻稿发布。
More
杰米·福克斯在Netflix喜剧特辑中讲述其健康危机细节
“` Latest News

杰米·福克斯在Netflix喜剧特辑中讲述其健康危机细节 “`

(SeaPRwire) - “我回来了!”杰米·福克斯在他的新喜剧特辑《What Had Happened Was…》开头哭着喊着。 对于一位上次喜剧特辑(2002年的音乐特辑《I Might Need Security》)已经是二十多年前的人来说,这并不是一个新颖的开场白,但从福克斯口中说出,这句话就意味深长了。2023年4月,他在亚特兰大拍摄《重返战场》时因“医疗并发症”住院,成为名人阴谋论谣言的焦点。根据你在过去一年里与谁交谈,原因从差点死亡到实际死亡,再到有人试图让他闭嘴而未遂的袭击,说法不一。在这个特辑中,他首次透露了实际发生的事情:他中风了。 如果有人担心《What Had Happened Was…》将会是一个特洛伊木马式的标题,以整个故事的承诺来诱导我们,然后用其他内容来取代它,那么这个担心立刻就消失了。特辑以他住院期间的新闻报道和阴谋视频片段开始,然后福克斯兴高采烈地走上舞台,宣称:“我很高兴还活着。” “你们不知道这感觉有多好,亚特兰大!”他说。“我当时在与死神搏斗,但我现在站在你们面前。”这个特辑兼具解释、脱口秀和崇拜环节,是福克斯写给亚特兰大这座他认为救了他性命的城市的爱情信。 在2023年的几个月里,围绕福克斯疾病的谜团达到了高潮,网络博客、右翼阴谋论者和流行文化参与者纷纷发表评论。尽管他的女儿科琳在特辑开头介绍了她父亲,说他正在康复,情况也很好。一些人认为他的病情比他们被告知的要严重得多,谣传他处于昏迷状态或遭受了严重的致残影响。另一些人更进一步,声称他实际上已经去世,家人正在向公众隐瞒这一消息。反疫苗活动家抓住这一新闻,声称他的病情是新冠疫苗的副作用。另一个特别耸人听闻、毫无根据的谣言是,福克斯在据称被拍到拍摄(Combs目前面临)后被(P Diddy)下毒,迅速传播开来。 “网上说Puffy试图杀我。绝对不会,我早早就离开了那些派对。有些事情看起来不对劲,这里很滑,”他在常规表演中第一次(但绝对不是最后一次)调侃P Diddy。 在长达一小时的表演中,福克斯坦诚地讲述了他过去一年的人生经历。在此之前,他和家人一直对他的病情细节保密,只透露了一些小细节。2023年7月,福克斯首次打破沉默,在Instagram上告诉他的粉丝们:“我知道很多人都在等待或想听到最新消息,但说实话,我只是不想让你们看到我那样。”他接着说:“我不想让你们看到我身上插着管子,试图弄清楚我能不能挺过去。” 他说他想让人们看到他在舞台上跳舞和大笑,这正是他在《What Had Happened Was…》中所做的。他开始跳舞,并与观众开玩笑,谈论他行动自如的情况,当他详细描述了他面临的严重医疗挑战时,这更有力量。 关于中风,他说:“这是一个谜,我们仍然不知道究竟发生了什么,”他详细描述了他在晕倒前遭受了剧烈头痛。“我不记得20天了,”他说,因为他为观众和自己拼凑着时间线。“他或许能够完全康复,但这将是他人生中最糟糕的一年,”他说医生告诉家人他脑出血很严重。“这就是情况,亚特兰大。你终于听到了完整的故事。” 与互联网上大多数阴谋论一样,真相往往远不如最离奇的理论那么有趣。但不太有趣并不意味着不重要,福克斯庄严地表达了重新学习站立、行走和自己清洁身体时的情感动荡。特辑的很大一部分是对他对上帝信仰的回归之旅,他像一位充满激情的牧师在山上分享一样分享了这一点。他带领大家唱赞美歌,并讲述了他与上帝的争论,关于他是否应该承受这种痛苦,他告诉狂热的观众,上帝通过他的家人和医生帮助他恢复健康。 在一个特别感人的时刻,福克斯带出了他最小的女儿安妮莉丝,他说她通过在医院病房里为他演奏吉他将他从死亡边缘拉了回来。她说她一直都想有机会一起演出,当她演奏她的歌时,福克斯一边抱着她的肩膀,一边哭了起来。 《What Had Happened Was…》与其说是一个喜剧特辑,不如说是一场生命的庆祝。在最搞笑的时刻,例如福克斯讲述他在康复期间与哈莉·贝瑞互动的一段,以及模仿丹泽尔·华盛顿和卡特·威廉姆斯等人的一段,福克斯的喜剧时机如此巧妙,以至于你会忘记他已经二十年没有做过脱口秀了,而他一直在忙于各种各样的工作,从他奥斯卡获奖的演出到——更不用说获得格莱美奖了。 但在很大程度上,特辑的幽默感来自于福克斯处理痛苦的方式,他一定会永远不会贬低或不尊重这种痛苦。“我从未放弃我的幽默感,”他说,当谈到康复时,他不得不吞下自尊。他贯穿整场表演的口号是:“如果我能保持幽默,我就能活下去。” 在特辑最后激动人心的时刻,福克斯大胆地利用关于他最离谱的阴谋——他实际上是一个克隆人,取代了原来的杰米·福克斯——将其变成了对自我的庆祝。“世界上没有足够的克隆液来克隆我,”他对着人群喊道。“我是不可克隆的,”他说,因为他回顾了他从《活色生香》到《雷》等最具代表性的角色。最终以坎耶·韦斯特的《Gold Digger》的狂喜表演告终,这首歌他最初有参与演出,他成功地将其重新定义为终极赞美歌。 福克斯在离开舞台前说的最后一句话是“谢谢”。他感谢了他的家人、医生、护理人员、医院、观众和上帝。他甚至感谢那些在网上散布关于他的谎言的人,但在先前的“去你的”之后。本文由第三方内容提供商提供。SeaPRwire (https://www.seaprwire.com/)对此不作任何保证或陈述。 分类: 头条新闻,日常新闻 SeaPRwire为公司和机构提供全球新闻稿发布,覆盖超过6,500个媒体库、86,000名编辑和记者,以及350万以上终端桌面和手机App。SeaPRwire支持英、日、德、韩、法、俄、印尼、马来、越南、中文等多种语言新闻稿发布。
More
MEDIROM Mother Labs的两名高级管理人员以90亿日元(截至2024年12月1日,约合5900万美元)的估值投资Mother Labs A轮融资 Business

MEDIROM Mother Labs的两名高级管理人员以90亿日元(截至2024年12月1日,约合5900万美元)的估值投资Mother Labs A轮融资

(SeaPRwire) - 东京,2024年12月11日 -- MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM)(“公司”或“MEDIROM”)宣布,两位高级管理人员,MEDIROM MOTHER Labs Inc.(“Mother Labs”,MEDIROM子公司)的首席技术官本間一生先生和Mother Labs的首席商务官速水康宏先生,已投资Mother Labs的A轮融资,估值达90亿日元(截至2024年12月1日,约合59,000,000美元)。本間先生和速水先生是Mother Labs的资深高管,他们认同MEDIROM的企业理念和愿景,并致力于公司的未来增长潜力。 关于本間一生先生和速水康宏先生的更多信息 MEDIROM MOTHER Labs Inc.首席技术官本間一生 2007年 创立Aratana Inc.并担任高级常务董事2015年 Aratana Inc.成为Start Today Inc.的全资子公司2018年 ZOZOUSED Inc.开发部经理2019年 创立Time Design LLC,担任首席执行官2024年 MEDIROM MOTHER Labs首席技术官 MEDIROM MOTHER Labs Inc.首席商务官速水康宏 1996年 创立INIT Co., Ltd.并担任代表董事2004年 transcosmos inc.执行董事2014年 创立Wise, Inc.2024年 被任命为MEDIROM Rehab Solutions, Inc.董事长2024年 MEDIROM MOTHER Labs首席商务官 无要约或招揽 本新闻稿及其中包含的信息不构成,也不构成在美国或任何其他州或司法管辖区出售任何证券的要约或购买任何证券的要约招揽,也不得在任何此种要约、招揽或出售属非法的司法管辖区出售任何证券。 关于MEDIROM的前瞻性声明 本新闻稿中的某些陈述是根据1995年美国《私人证券诉讼改革法案》的安全港条款而作出的前瞻性陈述。前瞻性陈述可能包括关于MEDIROM可能的或假设的经营业绩、财务状况、商业战略和计划、市场机会、竞争地位、行业环境和潜在增长机会的估计或预期。在某些情况下,可以通过诸如“可能”、“将”、“应该”、“设计”、“目标”、“旨在”、“希望”、“预期”、“可能”、“打算”、“计划”、“预期”、“估计”、“相信”、“继续”、“预测”、“预测”、“潜力”、“目标”或其他表达未来事件或结果不确定性的词语来识别前瞻性陈述。这些陈述与未来事件或MEDIROM未来的财务业绩有关,并涉及已知和未知的风险、不确定性和其他因素,这些因素可能导致MEDIROM的实际结果、活动水平、业绩或成就与这些前瞻性陈述中明示或暗示的任何未来结果、活动水平、业绩或成就不同。您不应过分依赖前瞻性陈述,因为它们涉及已知和未知的风险、不确定性和其他因素,在某些情况下,这些因素超出了MEDIROM的控制范围,并且可能并且很可能影响实际结果、活动水平、业绩或成就。任何前瞻性陈述都反映了MEDIROM对未来事件的当前看法,并受这些以及与MEDIROM的运营、经营业绩、增长战略和流动性相关的其他风险、不确定性和假设的影响。 有关这些风险以及可能影响MEDIROM的业务、声誉、经营业绩、财务状况和股价的其他潜在因素的更多信息,包含在MEDIROM提交给美国证券交易委员会(“SEC”)的文件中,包括在MEDIROM最近提交的20-F表格定期报告以及后续提交文件的“风险因素”和“经营和财务回顾与展望”部分,这些文件可在SEC网站www.sec.gov上获得。即使未来获得新信息,MEDIROM也不承担更新或修改这些前瞻性陈述的义务,也不承担更新实际结果可能与这些前瞻性陈述中预期的结果不同的原因的义务。 关于MEDIROM MOTHER Labs Inc.MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM)的子公司,专注于健康科技领域。公司核心业务包括通过“Lav”健康应用程序提供的“特定健康指导计划”,以及24/7免充电MOTHER Bracelet智能追踪器的开发和销售。通过利用免充电MOTHER Bracelet的功能,MOTHER Labs为包括护理、物流、制造等多个行业提供可定制的健康管理解决方案。 MEDIROM Healthcare Technologies Inc.纳斯达克股票代码:MRM东京贸易皮亚台场,东京都港区台场2-3-1网址 联系方式: MEDIROM MOTHER Labs Inc.东京贸易皮亚台场,东京都港区台场2-3-1MOTHER Bracelet是全球首款*24/7免充电智能追踪器。它采用来自硅谷科技公司的创新技术,可以根据人体与周围空气的温差发电。免充电功能消除了设备脱下充电时数据丢失的风险。MOTHER Bracelet记录五个基本指标:心率、卡路里消耗量、体表温度、步数和睡眠。官方网站:本文由第三方内容提供商提供。SeaPRwire (https://www.seaprwire.com/)对此不作任何保证或陈述。 分类: 头条新闻,日常新闻 SeaPRwire为公司和机构提供全球新闻稿发布,覆盖超过6,500个媒体库、86,000名编辑和记者,以及350万以上终端桌面和手机App。SeaPRwire支持英、日、德、韩、法、俄、印尼、马来、越南、中文等多种语言新闻稿发布。
More
加强多边主义:御泉国际论坛首次登陆欧洲 Business

加强多边主义:御泉国际论坛首次登陆欧洲

(SeaPRwire) - 广州,中国,2024年12月11日 -- 从当地时间12月11日至12日,2024年御泉国际论坛 (ISIF) 将在西班牙马德里举行,汇集来自50多个国家和地区的政治、学术和商业界的200多名参与者。作为中国最高级别的国际民间交流平台之一,本次论坛标志着该论坛首次在华以外举办,将活动带到欧洲。该论坛预计将加强中国与世界各国人民之间的交流,并促进合作以应对共同的全球挑战。 自2014年成立以来,ISIF 吸引了200多名前国家元首和政府首脑、国际组织领导人以及来自40多个国家的600多位杰出专家、学者和商界领袖。 在过去十年中,与会者赞扬该论坛保持全球视野,在关注长期发展的同时,解决当前问题。它为增进中国与世界相互理解,促进全球对话与合作,并为支持全球治理体系改革提供见解和建议做出了宝贵贡献。 澳大利亚中国友好交流协会主席、亚太地区世界领导联盟-马德里俱乐部主席圆桌会议主席、尼扎米·甘贾维国际中心全球圆桌会议联合主席周焯明博士认为,当今世界和平与发展面临着严峻挑战。“作为‘地球村’的一员,无论我们的角色或职业如何,我们都肩负着维护和平、促进全球合作与进步的共同使命、责任和义务。自成立以来,ISIF 一直是相互尊重、加深理解、增强信任和扩大共识的灯塔。今年在西班牙马德里举行论坛的决定,突显了我们朋友圈子的扩大、友谊的加强以及我们共同视角的丰富。” 周博士强调,随着世界进入一个新的转型时代,在许多领域都面临着关键性的决策,我们必须勇于创新以应对挑战,并坚定不移地致力于和平与发展——这是人类永恒的道路。通过集体努力和共同行动,我们可以为子孙后代创造一个更加和平、包容和和谐的世界。 2024年御泉国际论坛的主题为“为一个未来采取集体行动”,将举办十多项主要活动,包括开幕式、两次闭门会议、全体讨论、六个专题会议和闭幕式。主要议题包括“全球战略稳定”、“发展融资,迈向充分落实可持续发展目标”、“加强全球合作:塑造人类共同的未来”、“对全球安全的传统和非传统挑战”、“应对世界经济面临的挑战”、“联合国未来首脑会议,全球治理的未来”、“人工智能与绿色技术促进进步与发展”、“可持续发展和第二届世界社会首脑会议”以及“促进相互理解的人际交流”。这些讨论将涵盖安全、经济、技术、社会和文化等领域最紧迫的全球问题,同时兼顾多样性并关注未来。该论坛旨在从共享的人类视角汇聚集体智慧,寻求反映普遍价值观和利益的解决方案。 来源:2024年御泉国际论坛 (ISIF)本文由第三方内容提供商提供。SeaPRwire (https://www.seaprwire.com/)对此不作任何保证或陈述。 分类: 头条新闻,日常新闻 SeaPRwire为公司和机构提供全球新闻稿发布,覆盖超过6,500个媒体库、86,000名编辑和记者,以及350万以上终端桌面和手机App。SeaPRwire支持英、日、德、韩、法、俄、印尼、马来、越南、中文等多种语言新闻稿发布。 联系人:王先生,电话:86-10-63074558
More
引领绿色高效矿业发展 | MicroBT在2024年比特币中东非峰会发布新一代WhatsMiner M6XS++系列 Business

引领绿色高效矿业发展 | MicroBT在2024年比特币中东非峰会发布新一代WhatsMiner M6XS++系列

(SeaPRwire) - 阿布扎比,阿拉伯联合酋长国,2024年12月11日 -- 全球领先的比特币ASIC制造商MicroBT在阿布扎比举行的2024年比特币中东非会议上,通过推出最新的WhatsMiner M6XS++系列,再次展示了其技术实力和创新驱动的方法。 在会议期间,MicroBT创始人兼首席执行官杨佐星博士发表了题为“引领伟大而绿色的矿业发展”的主旨演讲。在他的演讲中,他揭示了太阳能矿业技术的进步,强调了水冷矿业系统中创新的热利用,并介绍了新的WhatsMiner型号。 矿业正处于一个关键时刻,绿色矿业正成为未来发展的前沿趋势。杨博士强调了太阳能矿业的变革潜力,预测到2025年,太阳能矿业的电力成本将大幅降低至每千瓦时约3.4美分。此外,WhatsMiner突破性的高温水出口水冷技术正在推动全面热回收的界限。这项技术使WhatsMiner水冷系统能够最大限度地减少矿业冷却需求,或将热量重新用于高级应用,例如工业蒸汽生产、海水淡化和加热系统,从而巩固了MicroBT在绿色矿业领域的突出地位。 随后,杨博士发布了最新一代的WhatsMiner产品。风冷式M60S++的算力高达226 TH/s,功耗为15.5 J/T。水冷式M63S++的算力高达478 TH/s,功耗保持在15.5 J/T。同时,浸没式冷却的M66S++的算力高达356 TH/s,功耗也为15.5 J/T。 此外,WhatsMiner系列还包括风冷式M61S+,其算力高达236 TH/s,功耗为17 J/T。水冷式M64S+和M65S+的算力分别高达236 TH/s和440 TH/s,功耗均为17 J/T。值得注意的是,M64S+和M65S+的出口水温最高可达80°C。 总之,杨博士自豪地宣布MicroBT坚定致力于开拓可持续和环保的矿业实践,预示着绿色矿业卓越和远见卓识领导力的一个新时代。随着最新WhatsMiner产品的发布,MicroBT已准备好并充满信心,果断地引领绿色矿业革命。 关于MicroBT MicroBT () 是一家基于区块链的技术公司,专注于集成电路芯片和产品的研发、生产和销售,并提供高性能计算系统解决方案和技术服务。MicroBT已在美国启动了比特币矿机制造业务。 关于WhatsMiner WhatsMiner () 是MicroBT开发的领先的矿机硬件和芯片设计品牌。作为市场上最高效和最具成本效益的矿机品牌之一,WhatsMiner被全球零售和机构矿商广泛使用。 联系方式:Elsa Zhao 免责声明:本内容由MicroBT提供。本专栏中表达的陈述、观点和意见仅代表内容提供商的观点。本新闻稿中提供的信息并非投资邀约,也不构成投资建议、财务建议或交易建议。强烈建议您在投资或交易加密货币和证券之前进行尽职调查,包括咨询专业财务顾问。请自行研究并自担风险投资。 本公告附带照片可在以下网址获取:本文由第三方内容提供商提供。SeaPRwire (https://www.seaprwire.com/)对此不作任何保证或陈述。 分类: 头条新闻,日常新闻 SeaPRwire为公司和机构提供全球新闻稿发布,覆盖超过6,500个媒体库、86,000名编辑和记者,以及350万以上终端桌面和手机App。SeaPRwire支持英、日、德、韩、法、俄、印尼、马来、越南、中文等多种语言新闻稿发布。
More
CGTN:潮起澳门:经济多元化发展迈向新高度 Business

CGTN:潮起澳门:经济多元化发展迈向新高度

(SeaPRwire) - CGTN发表了一篇文章,讲述澳门在过去25年是如何推动经济多元化的北京,2024年12月11日 -- 惠浩杰,一位刚刚完成加州学业的本科生,带着将中国大陆的尖端机器人技术带到家乡——中国澳门特别行政区(SAR)的新使命回到家乡。他利用粤港澳大湾区(GBA)提供的资源和机遇,成功建立了自己的企业,并融入该地区不断发展的科技生态系统。 惠浩杰表示,大湾区的创业环境是独一无二的。“每个城市都发挥自身的优势——澳门拥有与葡萄牙相关的资源,香港在金融方面实力雄厚,深圳在智能制造方面处于领先地位。(它们)协同合作非常紧密便捷。” 他的故事凸显了澳门正在发生的一个关键转变,即曾经依赖博彩业的经济现在正在拥抱新的产业。 自1999年回归中国以来,澳门发生了翻天覆地的变化。它历史上以赌场和旅游业而闻名,但一直在稳步转向经济多元化。大湾区在这个转型过程中发挥了至关重要的作用,为澳门发展科技、金融和文化等产业提供了工具。如今,随着其融入这一更广泛的区域框架,澳门不仅是旅游中心,更是创新中心。 去年11月,澳门特别行政区政府发布了2024年至2028年澳门适度多元化发展规划。该文件概述了发展旅游休闲、中医药和大健康、现代金融、新兴及高科技、会展以及文化体育等产业的具体规划和安排。 这项规划与一个突出澳门在推动科技创新方面作用的增长趋势相吻合。近年来,澳门高等院校产学研合作收入和专利项目数量持续增长。去年,产学研合作收入约达4.75亿澳门元(约合5920万美元)。2019年至2024年9月,共获得专利340余项。澳门也越来越积极地与大陆更广泛的太空探索目标相协调,于去年5月在酒泉卫星发射中心发射了首颗空间科学卫星。 澳门多元化战略的另一个关键部分是推广大型活动,例如国际烟花比赛、国际音乐节和格兰披治大赛车。这些活动每年吸引数百万游客,有助于为澳门经济注入新的活力,并减少其对博彩等传统支柱产业的依赖,从而增强其作为国际旅游目的地的声誉。 基础设施建设是推动澳门经济发展变化的另一股动力。粤澳深度合作区在横琴(广东省珠海市的一个区)的建立,极大地改善了澳门与珠海等邻近城市的互联互通。1月至10月,珠澳之间最繁忙的口岸——拱北口岸出入境人次超过9000万,日均超过30万。这种人员、货物和服务的无缝流动增强了澳门作为区域枢纽的作用,有利于贸易、旅游和跨境合作。 城市规划也发生了变化,重点是更有效地利用土地和可持续发展。目前,澳门约30%的新土地开发正在合作区进行,促进了跨境合作和空间优化。这种战略性的土地开发,加上改进的基础设施,正在增强澳门的整体可持续性及其在大湾区内的融合,从而确保城市能够持续以平衡、可持续的方式发展。 更多信息,请点击:本文由第三方内容提供商提供。SeaPRwire (https://www.seaprwire.com/)对此不作任何保证或陈述。 分类: 头条新闻,日常新闻 SeaPRwire为公司和机构提供全球新闻稿发布,覆盖超过6,500个媒体库、86,000名编辑和记者,以及350万以上终端桌面和手机App。SeaPRwire支持英、日、德、韩、法、俄、印尼、马来、越南、中文等多种语言新闻稿发布。 CONTACT: Contact: cgtn@cgtn.com
More
小鹏G6荣获五星级ANCAP安全评级
“` Business

小鹏G6荣获五星级ANCAP安全评级 “`

世界一流的安全性能再次印证了小鹏汽车对乘员和道路使用者保护的承诺 (SeaPRwire) - 广州,中国,2024年12月10日 -- 小鹏汽车(“小鹏”或“公司”,纽交所代码:XPEV,港交所代码:9868),一家领先的中国高科技汽车公司,自豪地宣布其纯电动超智能轿跑SUV,小鹏G6,获得了澳大利亚新车评估规划(ANCAP)的五星安全评级。 这一高评级突显了其在关键评估领域(包括成人乘员保护、儿童乘员保护、易受伤害道路使用者保护和安全辅助)的卓越安全性能。G6配备先进的安全功能,在碰撞测试中表现出色,在侧面碰撞和斜杆碰撞测试中均获得满分。 小鹏G6的主动安全系统也获得了高度赞扬。其全面的套件包括针对各种场景的自动紧急制动 (AEB)——车对车、易受伤害的道路使用者和摩托车手的保护——所有这些都获得了极高的分数。此外,其强大的车道保持系统和智能速度辅助系统进一步增强了道路安全。 创新的结构设计选择确保了G6运行时的被动安全高标准。该车采用中国首创的集成前后压铸技术,高强度铝制车架包含51%的铝合金。这种设计优化了碰撞时的载荷分布,降低了入侵风险,同时实现了轻量化、高刚度的车身,这对乘员安全至关重要。 电池安全是小鹏创新的基石,这得益于尖端技术,包括无热失控设计、多层隔热屏障和双回路液冷系统,即使在极端条件下也能保证稳定性。 此前,小鹏G6 SUV的国际版车型于2024年9月获得了Euro NCAP的五星安全评级。 小鹏汽车副董事长兼总裁顾宏地表示:“此次获得ANCAP五星安全评级,凸显了小鹏汽车卓越的安全标准,并强化了我们致力于提供行业领先的安全创新的承诺。我们内部的工程团队始终站在技术前沿,确保每一辆小鹏汽车不仅能为乘客提供卓越的保护,还能通过先进的系统和智能设计主动提升道路安全。” 关于小鹏汽车小鹏汽车成立于2014年,是一家领先的中国人工智能驱动的移动出行公司,致力于设计、开发、制造和销售智能电动汽车,服务于不断壮大的精通技术的消费者群体。随着人工智能的快速发展,小鹏汽车致力于成为全球人工智能移动出行领域的领导者,其使命是通过尖端技术推动智能电动汽车革命,塑造未来的出行方式。 为了提升客户体验,小鹏汽车自主研发全栈式高级驾驶辅助系统 (ADAS) 技术和智能车载操作系统,以及动力总成和电子电气架构 (EEA) 等核心车辆系统。小鹏汽车总部位于中国广州,还在北京、上海、硅谷和阿姆斯特丹设有主要办事处。其智能电动汽车主要在其位于广东省肇庆和广州的工厂生产。 小鹏汽车在纽约证券交易所(NYSE: XPEV)和香港交易所(HKEX: 9868)上市。 更多信息,请访问。 联系方式: 媒体查询: 小鹏公关部 邮箱: 来源:小鹏汽车本文由第三方内容提供商提供。SeaPRwire (https://www.seaprwire.com/)对此不作任何保证或陈述。 分类: 头条新闻,日常新闻 SeaPRwire为公司和机构提供全球新闻稿发布,覆盖超过6,500个媒体库、86,000名编辑和记者,以及350万以上终端桌面和手机App。SeaPRwire支持英、日、德、韩、法、俄、印尼、马来、越南、中文等多种语言新闻稿发布。
More
BOM Network Unveils Solutions to Tokenize Real-World Assets SeaPRwire

BOM Network Unveils Solutions to Tokenize Real-World Assets

Hong Kong – December 11, 2024 – (SeaPRwire) – Recently, BOM Network is proud to unveil its solutions to tokenize a wide range of real-world assets, from real estate to commodities, and use these tokens for trading, lending, or as collateral. Real-World Assets (RWA): The Bridge Between Traditional Finance and Blockchain Revolution In recent years, the crypto market has undergone remarkable growth, but its volatility and limited real-world use cases have often raised concerns. Real-World Assets (RWA) are emerging as a pivotal trend that may fundamentally reshape the blockchain and crypto space by creating a more stable and tangible connection to traditional finance. The tokenization of RWAs allows for real estate, commodities, and other physical assets to be represented on the blockchain, unlocking liquidity and expanding investment opportunities.RWAs bridge the gap between traditional assets and decentralized finance (DeFi), bringing stability, security, and trust into the often volatile crypto markets. This fusion offers several key benefits: Access to Illiquid Assets Increased Liquidity and Market Efficiency Global Access The Future of Banking and RWA Integration BOM Network is one standout project in the RWA space, focusing on integrating blockchain with traditional financial services. BOM Network’s unique approach lies in its emphasis on combining traditional banking services with the efficiency of blockchain, making it an attractive solution for institutions looking to bridge the gap between old and new financial systems. BOM Network has already established partnerships with global financial institutions, offering a scalable and secure way for investors to participate in the RWA market. Its platform is designed for both retail and institutional investors, making it a key player in the future of decentralized finance. By integrating RWAs into its ecosystem, BOM Network aims to drive the mainstream adoption of blockchain technology and create a more efficient, liquid, and globally accessible financial system. As the tokenization of RWAs gains traction, projects like BOM Network are leading the charge toward a more stable, diversified, and globally inclusive crypto market. About BOM Network BOM is the perfect bridge for capital from the real world to the Blockchain world. Meet a huge supply and demand of borrowing and lending from the real world into the cryptocurrency market. RWAs are likely to accelerate institutional adoption of blockchain technology. Moreover, the introduction of RWAs will catalyze regulatory development as governments and financial authorities adapt to this new intersection of traditional assets and blockchain technology. This convergence will bring crypto further into the mainstream, providing a fertile ground for innovation and growth. Social Links X: https://x.com/BOM_Network Telegram: https://t.me/BOMNetworkCommunity YouTube: https://www.youtube.com/@bom_network Media Contact Brand: BOM Network Contact: Media contact Email: support@bomnetwork.io Website: https://bomnetwork.io The article is provided by a third-party content provider. SeaPRwire ( https://www.seaprwire.com/ ) makes no warranties or representations in connection therewith. Sectors: Top Story, Corporate News SeaPRwire provides real time press release distribution for companies and organizations to 6,500+ media outlets & 3.5 million professional desktops in 90 regions. It distributes press releases in different languages, including: IndonesiaFolk, IndoNewswire, SEATribune, IDNewsZone, LiveBerita, DailyBerita, TaiwanPR, SinchewBusiness, AsiaEase, BuzzHongKong, SingapuraNow, TIHongKong, TaipeiCool, TWZip, AsiaFeatured, dePresseNow, THNewson, KULPR, VNFeatured, MENAEntry, HunaTimes, DubaiLite, ArabicDir, BeritaDaring, TekanAsia, JamKopi ...
More

云顶新耀:加速肾病领域创新 迈向全球生物制药领先地位

香港, 2024年12月11日 - (亚太商讯 via SeaPRwire.com) - 据《南华早报》报道,云顶新耀(HKEX 1952.HK)正加速实现其成为亚太地区领先生物制药企业的愿景。公司凭借强大的研发实力与卓越的商业化能力,在持续推动业务发展的同时,不断深化在全球生物制药领域的布局。近期,云顶新耀在核心商业化产品和突破性研究方面取得了一系列重要的里程碑式进展,充分体现了其在为亚洲乃至全球患者提供创新治疗解决方案方面的坚定承诺与卓越能力。这些成就不仅巩固了公司在行业中的领先地位,也进一步彰显了其致力于满足未被满足医疗需求的长期战略愿景。EVER001:肾病创新领域的突破2024年12月4日,云顶新耀宣布其自主研发且拥有全球权益的新一代共价可逆布鲁顿酪氨酸激酶(BTK)抑制剂EVER001,在1b/2a期临床试验阶段性数据中取得积极结果。本次试验聚焦原发性膜性肾病(pMN),是成人原发性肾病综合征的主要原因,存在未被满足的医疗需求。近年来,中国pMN的发病率持续上升,成为继IgA肾病(IgAN)后的第二大肾病综合征常见的病理类型。目前,中国约200万原发性膜性肾病患者,而在美国约有8万-10万患者,欧洲约8万患者,日本约4万患者,疾病负担在全球范围内日益加重,且目前全球没有获批此适应症的药物。不同于传统的共价不可逆BTK抑制剂,EVER001采用独特的共价可逆机制,结合其强大的靶点结合力与良好的安全性特征,避免持续抑制带来的毒副作用。试验结果显示,抗-PLA2R自身抗体水平在数据截止日期时已达到接近100%的下降,而早在低剂量组的24周和高剂量组的12周,抗-PLA2R自身抗体下降已超过90%。此外,在已完成36周治疗的低剂量组患者中,81.8%的患者实现临床缓解,高剂量组中已完成24周治疗的患者已有85.7%实现临床缓解。除低剂量组的1例患者外,其他所有完成36周治疗的低剂量组患者,以及所有经24周治疗的高剂量组患者分别在36周和24周都实现了免疫学完全缓解。EVER001作为一款潜在的同类最佳产品,该结果不仅显示了EVER001在pMN治疗中的高选择性、优异的药代动力学特征、良好的安全性特征以及强大的靶点结合力,还凸显了其在其他自身免疫性肾病,如狼疮性肾炎(LN)、IgA肾病、微小病变病(MCD)和局部节段性肾小球硬化(FSGS)中的广阔适应症前景。凭借广泛的适应症前景、日益增加的疾病发病率以及全球范围内的开发权益,EVER001成为具有显著商业价值的"蓝海"资产。近年来,肾病治疗领域已成为医药创新与资本投资的热点,吸引了众多跨国制药巨头的目光。以2023年为例,Vertex Pharmaceuticals斥资49亿美元收购了Alpine Immune Sciences,以获取其针对肾脏自身免疫性疾病的先进疗法。同年,诺华(Novartis)以35亿美元收购了Chinook Therapeutics,从而获得两项处于后期开发阶段的罕见肾病治疗药物。这些交易不仅凸显了全球医药行业对肾病领域的重视,也进一步验证了该领域创新治疗方案的巨大潜力和市场价值。"双轮驱动"战略推动商业化成功云顶新耀通过核心产品耐赋康(R)进一步巩固了其在肾病治疗领域的领导地位。耐赋康(R)是全球首个获得FDA批准的IgA肾病(IgAN)对因治疗药物,同时也是中国首个获得IgA肾病适应症的对因治疗药物。该药物已成功纳入2024年国家医保药品目录,这一里程碑不仅显著提升了患者可及性,还将大幅推动市场渗透率,其相关政策将于2025年1月1日正式实施。自2024年5月在中国大陆商业化上市以来,仅一个月耐赋康(R)销售额即突破人民币1.673亿元。此外,该药物还在中国澳门、中国香港、中国台湾、韩国及新加坡获批,进一步彰显了云顶新耀在全球肾病领域的专业实力与市场影响力。云顶新耀的多元化产品组合还包括氟环素类抗菌药物依嘉(R)与自身免疫疾病治疗药物伊曲莫德(VELSIPITY(R))。依嘉(R)作为全球首个氟环素类抗菌药物,在国家卫生健康委抗菌药物临床应用与耐药评价专家委员会发起并主办的"依拉环素临床应用综合评价项目"中表现卓越,临床疗效分析显示,依拉环素治疗3天时的整体有效率为91.1%,治疗结束时整体有效率为90.1%。截至2024年上半年,依嘉(R)累计销售额已达到2.33亿元,充分体现了市场对其的高度认可和接受度。在自身免疫疾病领域,伊曲莫德(VELSIPITY(R))的商业化进程取得重要进展。该产品已在中国澳门和新加坡获批上市,并通过"港澳药械通"政策率先进入粤港澳大湾区,成为云顶新耀第三款商业化产品。近期,伊曲莫德的新药上市许可申请已在中国香港获正式受理,公司计划于今年底向中国大陆递交申请,进一步释放其市场潜力。在研发领域,经过临床验证的mRNA技术平台是公司自主研发的核心部分,公司将自主研发重点转向拥有全部知识产权和全球权益的mRNA肿瘤治疗性疫苗。作为公司长期研发战略的重要支柱,该平台已实现显著突破。2024年8月,云顶新耀启动一款个性化肿瘤疫苗EVM16的研究者发起的临床试验项目(IIT),该研究由北京大学肿瘤医院和复旦大学附属肿瘤医院发起。此外,公司还在积极推进基于mRNA的体内CAR-T项目,用于癌症和自身免疫性疾病的治疗,不断拓展其研发管线的潜在应用。本周一,云顶新耀股价创下52周新高,盘中最高达49.7港元,收盘47.85港元。自中期业绩公布以来,股价已实现翻倍,充分体现了市场对公司未来发展的强烈信心。通过"双轮驱动"战略,云顶新耀持续聚焦未被满足的医疗需求,尤其在肾病等关键领域表现出色,并以EVER001等突破性疗法推动业务增长。凭借强劲的财务势头和清晰的战略规划,云顶新耀正稳步迈向可持续增长,为患者和股东创造长期价值。 Copyright 2024 亚太商讯 via SeaPRwire.com.
More

Everest Medicines: Accelerating Innovation in Renal Disease to Forge a Path Toward Biopharma Leadership

HONG KONG, Dec 11, 2024 - (ACN Newswire via SeaPRwire.com) – As reported by the South China Morning Post today, Everest Medicines (HKEX 1952.HK) is accelerating its journey to become a leading biopharmaceutical company in the Asia-Pacific region, driven by robust R&D capabilities and exceptional commercialization expertise.Breakthroughs in Renal Disease Innovation with EVER001On December 4, Everest Medicines announced positive results in preliminary analysis of Phase 1b/2a clinical trial of EVER001, its next-generation, globally owned covalent reversible Bruton’s Tyrosine Kinase (BTK) inhibitor. The trial focuses on primary membranous nephropathy (pMN), a common pathological type of nephrotic syndrome in adults with significant unmet medical needs. The prevalence of pMN in China has been increasing, making it the second most common cause of nephrotic syndrome after IgA nephropathy (IgAN). Currently, there are approximately 2 million patients with pMN in China, 80,000 to 100,000 in the United States, 80,000 in Europe, and 40,000 in Japan,with incidence rates rising in recent years, reflecting its growing global disease burden.Unlike traditional covalent irreversible BTK inhibitors, EVER001 employs a novel covalent reversible mechanism that combines strong target binding with excellent selectivity, significantly reducing off-target toxicity. Positive results in preliminary analysis revealed promising outcomes, with over 90% reductions in anti-PLA2R antibodies and substantial improvements in proteinuria. Additionally, patients in the low-dose cohort who have completed 36 weeks of treatment, 81.8% achieved overall clinical remission, and 91% achieved immunological complete remission. In the high dose cohort, 85.7% patients achieved overall clinical remission and all patients achieved immunological complete remission by week 24. With no currently approved treatments for pMN, EVER001 represents a potentially best-in-class therapeutic candidate. These results highlight EVER001’s potential to deliver best-in-class efficacy and safety, making it a promising treatment not only for pMN but also for a range of other autoimmune glomerular diseases, including lupus nephritis (LN), IgAN, Minimal Change Disease (MCD), and focal segmental glomerulosclerosis (FSGS).With broad indication potential, rising disease prevalence, and Everest Medicines’ global rights, EVER001 represents a high-value asset in a “Blue Ocean” area with significant commercial potential. Kidney disease therapeutics have become a hotspot for innovation and investment in recent years, attracting major multinational pharmaceutical companies. For example, Vertex Pharmaceuticals acquired Alpine Immune Sciences this April for $4.9 billion to access its kidney autoimmune disease therapies. Similarly, Novartis acquired Chinook Therapeutics in June 2023 for $3.5 billion, gaining access to two late-stage treatments for rare, severe chronic kidney diseases.Driving Commercial Success with a Dual-Engine StrategyEverest Medicines continues to strengthen its leadership in nephrology with NEFECON(R), the first FDA-approved treatment for IgAN and the first etiological therapy for IgAN in China. Its inclusion in the 2024 National Reimbursement Drug List (NRDL) marks a significant milestone, enhancing patient accessibility and driving market penetration starting January 1, 2025. Since its commercial launch in May 2024, NEFECON(R) has generated RMB167 million in sales within its first month. The product is also approved in Macau, Hong Kong, Taiwan, South Korea, and Singapore, further cementing Everest’s expertise in nephrology.Everest’s diversified portfolio also includes XERAVA(R) and VELSIPITY(R). XERAVA(R), a novel broad-spectrum antibiotic, demonstrated an overall effectiveness rate of 90.9% after three days of treatment in the "Comprehensive Evaluation Project on the Clinical Application of Eravacycline", contributing RMB134 million in revenue in H1 2024. VELSIPITY(R), approved under the "Hong Kong and Macau Medicine and Equipment Connect" policy, is now available in three designated medical institutions within the Greater Bay Area. It has also received approvals in Macau and Singapore, with an NDA accepted in Hong Kong and plans for an NDA submission in Mainland China by year-end.Everest is accelerating innovation through its proprietary mRNA platform, a cornerstone of its long-term R&D strategy. In August 2024, Everest launched an Investigator-Initiated Clinical Trial for EVM16, a personalized mRNA cancer vaccine, at Peking University Cancer Hospital and Fudan University Cancer Hospital. The company is also advancing mRNA-based in vivo CAR-T programs for cancer and autoimmune diseases, expanding its pipeline’s potential.As of now, Everest Medicines reached a 52-week high of HKD 49.7, closing at HKD 47.85. Since announcing its mid-year results, the stock price has more than doubled, reflecting strong investor confidence. With its dual-engine strategy, Everest has positioned itself as a rising leader in the global biopharmaceutical industry, focusing on unmet medical needs, particularly in renal diseases, and breakthrough therapies like EVER001. Supported by strong financial momentum and a clear vision, Everest is poised for sustainable growth and lasting value for patients and shareholders. Copyright 2024 ACN Newswire via SeaPRwire.com.
More
Combating customer harassment: Fujitsu, Toyo University and Kokoro Balance Research Institute launch field trial on AI-powered training program JCN Newswire

Combating customer harassment: Fujitsu, Toyo University and Kokoro Balance Research Institute launch field trial on AI-powered training program

Tokyo and Kawasaki, Japan, Dec 11, 2024 - (JCN Newswire via SeaPRwire.com) - Fujitsu Limited, Toyo University Incorporated Educational Institution (Toyo University) and Kokoro Balance Research Institute today announced the commencement of a field trial on December 3, 2024, to develop a Training Program for Coping with Customer Aggression. This program leverages AI and incorporates insights from criminal psychology and mental health to tackle the growing societal issue of customer harassment, i.e., unreasonable or abusive behavior directed at staff by customers and clients.The program utilizes the “AI Tool for Experiencing Customer Aggression” developed using Fujitsu's generative AI technology, behavior change support technologies and Toyo University's expertise in criminal psychology. Fujitsu’s AI tool provides interactive feedback through the use of AI avatars and clarifies actions that can be taken to enhance participants' customer harassment response skills. To evaluate the program's effectiveness, Kokoro Balance Research Institute will leverage its mental health expertise to develop new psychological scales measuring customer service skills, stress management, and overall customer harassment response capabilities. Furthermore, the research partners will carry out a field trial with call center employees at Fujitsu Communication Services Limited (CSL), analyzing changes in participants' customer service skills, stress management, engagement, and subjective productivity to ensure the program's scientific validity.The full program is targeted for launch in fiscal 2025 with the goals of reducing the psychological burden of working people in customer service roles and contributing to the creation of safe and supportive work environments.BackgroundCustomer harassment has become a serious social issue. A recent survey revealed that 46.8% of service industry workers have encountered customer harassment in the past two years, with nearly half experiencing lasting physical and mental health consequences.In response, the Ministry of Health, Labour and Welfare added mental health issues related to customer harassment to its work-related injury recognition criteria in September 2023. Furthermore, the Tokyo Metropolitan Assembly passed Japan's first customer harassment prevention ordinance in October 2024. The growing national and local government efforts are driving increased organizational responsibility for employee protection.Field Trial PeriodDecember 3, 2024 to March 31, 2025Figure 1: Overview diagram of the field trial Comment from Akiko Yamada, Head of the Converging Technologies Laboratory of Fujitsu Research, Fujitsu Limited:We have been pursuing research in converging technologies, combining cutting-edge digital technology with knowledge from humanities and social sciences to solve various social issues. This new initiative combines generative AI, behavioral change support technology, criminal psychology, and mental health expertise to tackle the significant social problem of customer harassment and secure the well-being of working people.Comment from Prof. Masayuki Kiriu, Dean, Faculty of Sociology, Toyo University:By incorporating psychological scales and stress measurement indicators into the "AI Tool for Experiencing Customer Aggression”, we expect to create a practical and effective customer harassment response training program for customer service personnel. This will significantly contribute to solving current customer harassment issues. We anticipate the emergence of new social contributions through converging technology in this pilot program.Comment from Kyoko Shimada, Representative Director, Kokoro Balance Research Institute:Customer harassment can inflict deep emotional wounds on employees. While eradication may be impossible, we can reduce its impact through organizational efforts. This research aims to strengthen organizations by focusing on employee mental health and response capabilities. By using globally recognized psychological scales and effective evaluation criteria, we aim to make this program scientifically sound, useful, and applicable for employees.About FujitsuFujitsu’s purpose is to make the world more sustainable by building trust in society through innovation. As the digital transformation partner of choice for customers in over 100 countries, our 124,000 employees work to resolve some of the greatest challenges facing humanity. Our range of services and solutions draw on five key technologies: Computing, Networks, AI, Data & Security, and Converging Technologies, which we bring together to deliver sustainability transformation. Fujitsu Limited (TSE:6702) reported consolidated revenues of 3.7 trillion yen (US$26 billion) for the fiscal year ended March 31, 2024 and remains the top digital services company in Japan by market share. Find out more: www.fujitsu.com.Press Contacts:Fujitsu LimitedPublic and Investor Relations DivisionInquiriesToyo UniversityToyo University General Affairs Department, Public Relations DivisionPhone: 03-3945-7571Reception hours: 9:00-18:00 JST (excluding Saturdays, Sundays, holidays, and university-designated holidays)E-mail: mlkoho@toyo.jpKokoro Balance Research InstituteE-mail: info@kokorobalance.jp Copyright 2024 JCN Newswire via SeaPRwire.com.
More
China Medical System: First Prescriptions for Innovative Drug Lumeblue(R) Issued in China SeaPRwire

China Medical System: First Prescriptions for Innovative Drug Lumeblue(R) Issued in China

SHENZHEN, CHINA, Dec 9, 2024 – (ACN Newswire) – On 6 December, China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that the first prescriptions for the innovative drug Lumeblue® (Methylthioninium Chloride Enteric-coated Sustained-release Tablets) (the “Product”) have been issued in China, which marks that the first oral methylthioninium chloride enteric-coated sustained-release tablets in China has officially entered clinical application. The Product is indicated for enhancing visualization of colorectal lesions in adult patients undergoing screening or surveillance colonoscopies. Lumeblue® is an oral diagnostic drug that uses patented multi-matrix (MMXTM) technology to deliver active substances directly to the colon and release them locally in a controlled manner. As an enhancer dye, the Product increases the contrast between colorectal lesions and healthy mucosa. The results of the Phase III clinical trial in China show that the Product can significantly improve the detection rate of non-polypoid colorectal lesions (the primary endpoint of the study), leading to an improved detection rate of dangerous lesions such as non-polypoid adenomas (the secondary endpoint)[1]. In addition, the Product can be taken during the bowel preparation step, ensuring that colorectal staining is completed by the time colonoscopy is conducted. This not only enhances the detection rate of colorectal lesions but also potentially simplifies the colonoscopy procedure, making the examination more efficient and improving the screening benefits. According to the diagnosis and treatment data of the Digestive Endoscopy Branch of the Chinese Medical Association, approximately a total of 28 million gastroenteroscopies were completed nationwide in 2012, including 5.83 million colonoscopies. In 2019, approximately 38.73 million gastroenteroscopies were completed nationwide, an increase of 34.62% compared with 2012[2]. The Expert consensus on the early diagnosis and treatment of colorectal cancer in China (2023 edition) recommends colorectal cancer screening for individuals aged 40 to 74[3]. Based on the China Statistical Yearbook (2023), the total population of this age group in China is 643.36 million[4]. With the popularization of early colorectal cancer screening in China, the number of colonoscopies performed is expected to have significant growth potential in the future. Early diagnosis and removal of lesions are crucial for prevention. Lumeblue® provides an innovative solution for colorectal disease screening and management in response to this growing demand. The Product has been approved by the European Medicines Agency (EMA) to be commercialized in the European Union under the trade name Lumeblue® in August 2020. The Group obtained an exclusive license for the Product from Cosmo Technologies Ltd., a fully-owned subsidiary of Cosmo Pharmaceuticals NV, on 3 December 2020. Following its approval in China in June 2024, CMS worked collaboratively across its business segments to ensure the rapid importation of the first batch of products. The Group has also actively leveraged its existing gastroenterology portfolio and resources to orderly advance the commercialization and academic promotion of Lumeblue®, facilitating its successful prescriptions launch in China. With this milestone, CMS’s five innovative drugs have been successfully approved in China and fully entered clinical application. This achievement demonstrates the Group’s ongoing capability of innovation transformation, while reflecting CMS’s commitment to focusing on medical value and fulfilling its corporate social responsibility. Looking ahead, CMS will continue to be patients-centered, efficiently advancing the clinical development and commercialization of innovative products. The Group is dedicated to improving the accessibility and affordability of innovative drugs, benefiting a broader patient population. About CMS CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs. CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients. CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development of its advantageous specialty fields and expand business boundaries. While strengthening the competitiveness of the cardio-cerebrovascular/gastroenterology business, CMS independently operates its dermatology and medical aesthetics business, and ophthalmology business, aiming to gain leading positions in specialty therapeutic fields, whilst enhancing the scale and efficiency. At the same time, CMS has expanded its business territory to the Southeast Asian market, striving to become a “bridgehead” for global pharmaceutical companies to enter the Southeast Asian market, further escorting the sustainable and healthy development of the Group. References: 1. The results of the Product’s Phase III clinical trial in China were published and are available at: https://web.cms.net.cn/en/2022/12/positive-results-for-china-phase-iii-clinical-trial-of-methylthioninium-chloride-enteric-coated-sustained-release-tablets/ 2. Data from the Digestive Endoscopy Branch of the Chinese Medical Association 3. Early Diagnosis and Treatment Group of the Chinese Society of Oncology. “Expert Consensus on Early Diagnosis and Treatment of Colorectal Cancer in China (2023 Edition).” Chinese Medical Journal, 2023, 103(48): 3896-3908. DOI: 10.3760/cma.j.cn112137-20230804-00164 4. National Bureau of Statistics. (2023). China Statistical Yearbook 2023. Retrieved from https://www.stats.gov.cn/sj/ndsj/2023/indexch.htm CMS Disclaimer and Forward-Looking Statements This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert. This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.
More
FxPro Group Announces the Launch of BankPro: A Private Digital Banking Solution SeaPRwire

FxPro Group Announces the Launch of BankPro: A Private Digital Banking Solution

Nassau, the Bahamas – December 11, 2024 – (SeaPRwire) – FxPro Group, a global leader in financial services and trading, has launched BankPro, a cutting-edge Private Digital Bank designed to redefine digital financial solutions for individuals and corporations. BankPro combines private banking services with advanced investment and trading capabilities, offering clients a seamless, all-in-one application tailored to their financial needs. The launch of BankPro underscores FxPro Group’s commitment to innovation and excellence, leveraging its 25 years of expertise and $120 million in Tier 1 company capital to introduce a next-generation digital banking solution. BankPro is regulated by the Central Bank of The Bahamas and operates with the highest standards of security and compliance. Key Features of BankPro: Multi-Currency Accounts BankPro provides access to over 24 currencies, enabling effortless international transactions at competitive exchange rates. Clients can manage their finances globally with a single account designed for both personal and corporate use. Visa Platinum Cards Clients can access exclusive Visa Platinum cards, offering customizable spending limits, global acceptance, and enhanced security. Additionally, instant virtual cards provide a secure and efficient solution for online transactions, making BankPro a versatile option for all financial activities. Global Banking with Flat Fees BankPro simplifies international banking with flat-fee structures, ensuring transparent and predictable costs. This approach is particularly advantageous for high-value transactions, providing clarity and value for clients engaged in global business and personal finance. Comprehensive Investment and Trading Platform BankPro integrates investment and trading capabilities, allowing clients to manage and grow their portfolios within the same platform. Key features include: Investing in over 2,100 Stocks and ETFs: Clients gain access to major exchanges, including NYSE, Nasdaq, LSE, XETRA, and Euronext. Real-Time Market Data: Active subscriptions include free live pricing from Nasdaq and LSE. Through FxPro Global Markets Ltd., clients can also trade over 200 Derivatives across Forex, Commodities, Metals, Indices, Stocks, and ETFs, enabling portfolio diversification and risk management. Corporate Banking Solutions BankPro offers tailored services for businesses, including multi-currency accounts, streamlined expense management tools, and advanced treasury management solutions. Corporate clients benefit from high-spending Visa Platinum cards, detailed reporting tools, and access to flexible investment options. A Strong Foundation in the Bahamas BankPro operates from its state-of-the-art headquarters in Lyford Cay, Nassau. The facility reflects the company’s commitment to The Bahamas as a central hub for its operations. The company also has an office in the City of London, UK. As a fully regulated entity, BankPro prioritizes security and reliability, holding a professional membership with the Association of International Banks and Trust Companies. The company’s regulatory foundation ensures robust protection for clients, complemented by advanced digital onboarding tools and fraud prevention measures. These features, combined with the FxPro Group’s legacy of excellence, make BankPro a trusted partner for financial services. About FxPro Group With 25 years of experience, the FxPro Group is a global leader in financial services, offering trading solutions across Forex, Commodities, and more. With a presence in over 170 countries and $200+ million invested in elite sponsorships, FxPro has earned over 120 industry awards for its innovative technology and reliable services. The launch of BankPro marks the Group’s expansion into digital private banking, combining its expertise in trading with cutting-edge financial solutions designed for the modern client. To know more please contact +1 242 603 2226. Media Contact Brand: BankPro Limited Contact: Media team Email: info@bankpro.com Website: https://www.bankpro.com The article is provided by a third-party content provider. SeaPRwire ( https://www.seaprwire.com/ ) makes no warranties or representations in connection therewith. Sectors: Top Story, Corporate News SeaPRwire provides real time press release distribution for companies and organizations to 6,500+ media outlets & 3.5 million professional desktops in 90 regions. It distributes press releases in different languages, including: IndonesiaFolk, IndoNewswire, SEATribune, IDNewsZone, LiveBerita, DailyBerita, TaiwanPR, SinchewBusiness, AsiaEase, BuzzHongKong, SingapuraNow, TIHongKong, TaipeiCool, TWZip, AsiaFeatured, dePresseNow, THNewson, KULPR, VNFeatured, MENAEntry, HunaTimes, DubaiLite, ArabicDir, BeritaDaring, TekanAsia, JamKopi ...
More

顺丰控股进军港股 书写国际化发展新篇章

香港, 2024年12月10日 - (亚太商讯 via SeaPRwire.com) - 据经济日报报道,随着全球企业供应链的重塑、中国企业出海以及跨境电商的推动,市场对更高效、更灵活、更综合的物流服务的需求不断攀升。顺丰控股股份有限公司(「顺丰控股」,股份代号:6936.HK)以其独特的业务模式和强大的网络优势,积极布局国际物流服务,投身于时代革新发展的浪潮中。根据弗若斯特沙利文,按2023年收入计,顺丰控股是中国及亚洲最大的综合物流服务提供商,也是全球第四大综合物流服务提供商,仅次于联合包裹服务公司(UPS)、敦豪(DHL)和联邦快递(FedEx)。公开资料显示,顺丰控股连续多年位居《财富》世界500强企业之列。2024年,公司获评《财富》最受赞赏的中国公司第二位,且连续8年上榜「《财富》最受赞赏的中国公司」。11月27日,顺丰控股登陆港交所,掀开国际化发展新篇章。夯实物流基础网络 持续迎来盈利兑现顺丰控股最早于2010年即开始运营国际业务,主要服务中国客户的出境物流需求。如今,随着中国企业出海,国际供应链蕴含着重大转型机遇。2021年,公司携手嘉里物流,进一步强化了在东南亚的本土及跨境快递、国际供应链和国际货代能力。通过与嘉里物流的融通,其国际综合物流能力和客户基础得到进一步强化,为实现国际拓展的战略和愿景提供了重要助力。根据弗若斯特沙利文报告,按国际收入计,2023年顺丰的国际业务规模已在所有亚洲综合物流服务提供商中排名第一。值得关注的是,经过多年投入后,顺丰控股已度过资本开支的高峰期,迎来更高质量增长周期。一方面,业务规模扩张持续摊薄基础设施边际成本,提升其营业利润率。另一方面,公司新业务陆续进入"收获期",提供公司盈利弹性。具体而言,经济产品体系升级,助力利润稳步增长;大件业务于2022年净利润转盈,2023年在降本提效作用下盈利能力持续增厚;同城业务于2023年首次实现全年盈利,2024年延续高增长。得益于此,顺丰控股盈利能力持续增强,2024年前三季度,其收入同比增加9.4%,净利润同比增加28.0%。净利率达到3.7%,同比提升了0.5个百分点。未来,在上述因素的共同推动下,公司盈利能力有望进一步增强。加速推进国际业务 打开中长期成长空间对于顺丰控股而言,从亚洲到全球,是其发展的必然。为此,公司积极参与建设鄂州货运枢纽,作为亚洲第一、全球第四座以货运为主的物流枢纽,鄂州货运枢纽的投产将进一步扩大公司与同业在配送时效以及网络方面的差异化优势,促进公司降本增效,为国际业务拓展奠定了坚实的基础。随着位于鄂州货运枢纽的分拣及转运中心投入运营,凭借丰富的产品组合、综合的全球能力、并购经验、卓越的运营及精益的成本管控,顺丰控股能够有效整合市场并把握国内外的市场机遇。顺丰控股高管曾表示,赴港上市是出于国际化的长远考虑,最主要目的是利用全球化资本,实现规模快速扩张。本次上市,顺丰控股计划将募集资金的45%用于加强其国际及跨境物流能力,此将进一步提升公司国际产品的广度及深度,助力公司国际业务加速拓展。同时,H股上市也有助于提升公司品牌影响力及市场竞争力。在丰富的物流网络、领先的成本优势和综合物流能力的支撑下,顺丰控股有望抢占更大的全球市场份额,推动公司投资价值的不断增长。 Copyright 2024 亚太商讯 via SeaPRwire.com.
More
[Macao Products Receiving Wide Acclaim] Macao Companies Achieved Remarkable Success with Doubled Sales and Over 50 Business Matching Negotiations at the Singapore Food Expo SeaPRwire

[Macao Products Receiving Wide Acclaim] Macao Companies Achieved Remarkable Success with Doubled Sales and Over 50 Business Matching Negotiations at the Singapore Food Expo

The four-day “Asia Pacific Food Expo 2024” successfully concluded on Monday (Dec 9th), with over 50 business matching negotiations taking place at the Macao Pavilion. Macao exhibitors are satisfied with the outcomes, as “Made in Macao” and “Macao Brand” products have garnered substantial repurchases and inquiries. “Sales figures for a single day at the event surpass those typically seen in Macao on weekdays”. The heightened demand at the event has elevated the popularity of Macao products to a peak, establishing them as the preferred choice among Singaporean and international businessmen. Moreover, some exhibitors have successfully connected with the local supermarkets and food agents through interactions. Furthermore, some businessmen have shown optimism regarding Macao’s business environment and the significant potential of Halal catering market in general. They engaged in profound discussions with Macao enterprises on-site and expressed their intentions to establish a presence in Macao. [caption id="attachment_3184" align="aligncenter" width="1400"] Pictures:Alvin Tan Sheng Hui, Singaporean Minister of State for Trade and Industry, and other guests visited the Macao Pavilion[/caption] In Singapore, Ms. Elaine Wong, Member of Board of Directors of Macao Commerce and Investment Promotion Institute (IPIM), met with Honorary President Edward Liu and Executive Director Jan Tan of the Asian Federation of Exhibition and Convention Associations (AFECA) to promote the MICE advantages of Macao and Hengqin, and invited AFECA to hold conventions and exhibitions in Macao and Hengqin. Mr. Edward Liu expressed his intention to visit Macao and Hengqin for an inspection tour in 2025. Established in Singapore in 2005, AFECA currently has about 155 members, which are mainly the MICE industry associations in Asia. [caption id="attachment_3185" align="aligncenter" width="1492"] Pictures:IPIM representatives met with AFECA representatives[/caption] The “Consumption + Negotiation” Integrated Exhibition Aids Enterprises in Connecting with International Business Opportunities Organised by the Singapore Food Manufacturers’ Association, the “Asia Pacific Food Expo 2024” has an exhibition area of about 10,000 square meters. The event has drawn the participation of over 200 exhibitors from mainland China and Singapore, encompassing upstream, midstream and downstream industrial chain enterprises in the food and beverage industries. IPIM and the Industrial Association of Macau set up the Macao Pavilion, for the first time, at the “Asia Pacific Food Expo”, and organised the participation of 24 Macao SMEs and over 250 “Made in Macao”, “Macao Brand” products, of which nearly 80% were Halal-certified products or the distinguished “M Brand” quality products. [caption id="attachment_3186" align="aligncenter" width="1393"] Pictures:Crowds at the Macao Pavilion of the “Asia Pacific Food Expo 2024”[/caption] [caption id="attachment_3187" align="aligncenter" width="1399"] Pictures:IPIM and the Industrial Association of Macau set up the Macao Pavilion at the “Asia Pacific Food Expo 2024” for the first time to promote Macao products[/caption] [caption id="attachment_3188" align="aligncenter" width="1400"] Pictures:Macao products were very popular at the event[/caption] [caption id="attachment_3189" align="aligncenter" width="1400"] Pictures:Macao products were very popular at the event[/caption] [caption id="attachment_3190" align="aligncenter" width="1400"] Pictures:Local Internet influencers were invited to promote the Macao Pavilion[/caption] Throughout the four-day event, Macao exhibitors, and the buyers and visitors from around the globe all benefited significantly. According to the Macao enterprises, the diverse customer sources of the Expo enable them to swiftly comprehend and access the latest market trends, and to grasp the new consumption patterns of international customers. Furthermore, the “consumption + negotiation” integrated exhibition can function as a platform for testing the products and establishing business networks. Local Internet influencers were also invited to promote Macao companies’ brands and their charms at the Macao Pavilion. [caption id="attachment_3191" align="aligncenter" width="1400"] Pictures:Enterprises were exploring business opportunities at the Macao Pavilion[/caption] [caption id="attachment_3192" align="aligncenter" width="1400"] Pictures:The check-in booths featuring elements from Portuguese-speaking countries at the Macao Pavilion[/caption] Leveraging Insights from the Global Halal Food Sector to Craft the Golden Business Card for Halal Food in Macao At the event, exhibitors were delighted to witness the positive reception of Macao’s halal food by the visitors. Through the exhibition, they have recognised significant business prospects in Singapore and other halal food markets. They will leverage insights from the Singapore’s Halal food to upgrade Macao’s halal food production, in order to further enrich the experience of international visitors to Macao, thereby crafting Macao’s golden business card. [caption id="attachment_3193" align="aligncenter" width="1400"] Pictures:The on-site coffee brewing demonstration at the Macao Pavilion attracts crowds of visitors[/caption] [caption id="attachment_3194" align="aligncenter" width="1858"] Pictures:The on-site coffee brewing demonstration at the Macao Pavilion attracts crowds of visitors[/caption] Some visitors praised the layout and arrangement of the Macao Pavilion, which could let them fully feel the charm of Macao and quickly grasp the latest business information of Macao and Hengqin. The accurate connection with Macao enterprises for “one-on-one” negotiations also strengthened their intention to invest in Macao and Hengqin.
More
【澳门产品广获好评】澳企在新加坡参展喜获双收  销量翻倍促逾50场配对洽谈 SeaPRwire

【澳门产品广获好评】澳企在新加坡参展喜获双收 销量翻倍促逾50场配对洽谈

一连四天的“亚太国际食品展2024”于今(9)日圆满闭幕。澳门馆内促逾50场配对洽谈,展商们满意成效,“澳门制造”、“澳门品牌”的产品获得高回购及高查询,“单日货品销量至少是澳门平日的翻倍”,连日热销让澳门产品的知名度推至高点,成为新加坡以至国际客商的“心头好”;亦有展商成功连线当地商超、代理商等。此外,有与会客商看好澳门营商环境以及清真市场发展潜力庞大,即场与澳门企业开展深入交流,并有落户澳门计划。 [caption id="attachment_3184" align="aligncenter" width="1400"] 图片说明:新加坡贸易与工业部政务部长陈圣辉等嘉宾参观澳门馆[/caption] 赴新加坡期间,澳门特别行政区招商投资促进局委员黄伊琳会面亚洲展览会议协会联盟(AFECA)Honorary President Edward Liu及Executive Director Jan Tan,推介澳琴会展优势,亦诚邀该会赴澳琴办展办会。Edward Liu透露2025年有计划赴澳琴考察。AFECA于2005年在新加坡成立,现有会员单位约155个,主要来自亚洲地区的会展行业协会。 [caption id="attachment_3185" align="aligncenter" width="1492"] 图片说明:招商投资促进局代表会面亚洲展览会议协会联盟代表[/caption] “消费+洽商”一体展会助企业联通国际商机 “亚太国际食品展2024”由新加坡食品厂商联合会主办,展览面积约一万平方米,吸引来自中国内地、新加坡等逾200家展商参与,涵盖食品及饮料等行业的上中下游产业链企业。招商投资促进局联同澳门厂商联合会首次设置澳门馆,组织24家澳门中小企展销展示250多款“澳门制造”、“澳门品牌”产品,当中近80%澳门展商产品持清真认证或及“M唛”澳门产品优质认证。 [caption id="attachment_3186" align="aligncenter" width="1393"] 图片说明:“亚太国际食品展2024”的澳门馆人流络绎不绝[/caption] [caption id="attachment_3187" align="aligncenter" width="1399"] 图片说明:澳门特别行政区招商投资促进局联同澳门厂商联合会首次在“亚太国际食品展2024”设置澳门馆推广澳门产品[/caption] [caption id="attachment_3188" align="aligncenter" width="1400"] 图片说明:澳门产品受与会客商追捧[/caption] [caption id="attachment_3189" align="aligncenter" width="1400"] 图片说明:澳门产品受与会客商追捧[/caption] [caption id="attachment_3190" align="aligncenter" width="1400"] 图片说明:澳门馆内安排当地的网络达人穿梭走访展位[/caption] 四天展会澳门展商及世界各地与会客商均收获满满。有澳门企业代表指该展会客源多样,有助快速了解及获取市场最新动态,掌握客群的新型消费模式,而且展会集消费及洽商为一体,成为企业视作产品“试水”和建立商业网络的绝佳平台。澳门馆内还安排了当地的网络达人穿梭走访展位,助企业宣传推广品牌及产品魅力。 [caption id="attachment_3191" align="aligncenter" width="1400"] 图片说明:客商们在澳门馆内拓展商机[/caption] [caption id="attachment_3192" align="aligncenter" width="1400"] 图片说明:澳门馆内结合葡语国家元素打卡位吸引[/caption] 取经各地清真食品之长打造澳门清真食品新名片 同时展商喜见澳门清真食品获得不少客商好评,通过实地参展,了解到新加坡等清真食品市场商机巨大,会借镜新加坡清真等食品优点,融入到澳门清真食品升级箇中“内涵”,进一步满足并丰富国际客商的游澳体验,继而“升呢”成为澳门新名片。 [caption id="attachment_3193" align="aligncenter" width="1400"] 图片说明:澳门馆内咖啡佳酿即场制作示范引人流[/caption] [caption id="attachment_3194" align="aligncenter" width="1858"] 图片说明:澳门馆内咖啡佳酿即场制作示范引人流[/caption] 有与会客商点赞展馆布局及安排到位,充分感受到澳门魅力的同时,亦能快速掌握澳琴最新营商信息,并叠加精准对接澳门企业开展“一对一”洽谈,加强了在澳琴投资的意欲。
More
VisiRose Introduces Revolutionary Therapy for Severe Eye Infections ACN Newswire

VisiRose Introduces Revolutionary Therapy for Severe Eye Infections

KNOXVILLE, Tenn., Dec 10, 2024 - (ACN Newswire via SeaPRwire.com) - VisiRose, a clinical-stage biotechnology company, is introducing Rose Bengal Photodynamic Antimicrobial Therapy (RB PDAT), a groundbreaking, non-invasive investigational treatment for infectious keratitis and other serious eye infections developed by the University of Miami Miller School of Medicine's Bascom Palmer Eye Institute (BPEI). VisiRose, a newly launched company of Provectus Biopharmaceuticals (OTCQB:PVCT) and the University, is focused on commercializing this innovative ocular research by combining a formulation of Provectus's pharmaceutical-grade bioactive synthetic small molecule Rose Bengal Sodium (RBS) and BPEI's light-based medical device to treat eye infections caused by bacteria, fungi, and parasites.RB PDAT offers a potential solution to the growing global problem of antimicrobial resistance (AMR), providing a broad-spectrum ocular therapy that may be safe, effective, and cost-efficient. The treatment has shown rapid infection resolution and improved patient outcomes in clinical trials across the U.S., India, Brazil, and Mexico."RB PDAT is a revolutionary, non-invasive treatment showing remarkable promise for patients with severe infectious keratitis. This innovative therapy harnesses the power of light to combat infection and offers new hope for preserving vision," said Jean-Marie Parel, IngETS-G, Ph.D., FAIMBE, FARVO, Director and co-founder of the Ophthalmic Biophysics Center at BPEI.Guillermo Amescua, M.D., Professor of Clinical Ophthalmology, Medical Director of the Ocular Microbiology Laboratory, and a board-certified ophthalmologist at BPEI added, "VisiRose is crucial for translating the innovation of RB PDAT from the laboratory to a widely accessible treatment, ultimately benefiting countless patients worldwide.""VisiRose is the bridge that connects innovation with impact. It enables us to bring the hope of RB PDAT to patients who desperately need it, transforming lives and shaping the future of eye care," said Ed Pershing, Chairman of the Board of Directors of VisiRose and Provectus.Dominic Rodrigues, Acting CEO of VisiRose added, "RB PDAT offers a beacon of hope for patients facing the threat of vision loss from infectious keratitis. This innovative therapy, with its targeted action and dual benefits, represents a significant advancement in eye care, paving the way for a brighter future for those struggling with this challenging condition."In more than 500 patients, RB PDAT has shown promising results in treating severe eye infections where traditional therapies have failed. VisiRose is poised to address a significant gap in the $60 billion global ophthalmic market, focusing on regions and populations impacted by rising AMR and the lack of access to effective treatments.About VisiRoseVisiRose is a newly launched, clinical-stage biotechnology company of the University of Miami and Provectus Biopharmaceuticals, focused on commercializing the Miller School of Medicine's Bascom Palmer Eye Institute and its Ophthalmic Biophysics Center's innovative ocular research using Provectus's bioactive synthetic small molecule Rose Bengal Sodium (RBS). For more information, please visit: https://visirose.com.About Bascom Palmer Eye InstituteThe Bascom Palmer Eye Institute, part of the University of Miami Health System, is consistently ranked #1 in ophthalmology in the U.S. by U.S. News & World Report. Known for its cutting-edge research and clinical excellence, Bascom Palmer provides world-class care across all ophthalmic subspecialties and is at the forefront of developing innovative treatments for eye diseases. With a commitment to advancing both patient care and medical research, it is recognized globally as a leader in ophthalmology. For more information, please visit: https://umiamihealth.org/en/bascom-palmer-eye-institute.About Provectus BiopharmaceuticalsProvectus Biopharmaceuticals (OTCQB: PVCT) is a clinical-stage biotechnology company developing immunotherapy medicines for different diseases that are based on a class of bioactive synthetic small molecules called halogenated xanthenes. The Company's lead molecule is named Rose Bengal Sodium. Provectus's drug platform includes:Clinical development programs in oncology, dermatology, and ophthalmology,In vivo proof-of-concept programs in oncology, hematology, full-thickness cutaneous wound healing, and canine cancers, andIn vitro discovery programs in infectious diseases, tissue regeneration and repair, and several proprietary targets.Information about the Company's clinical trials can be found at the National Institutes of Health (NIH) registry, www.clinicaltrials.gov. For more information, please visit: www.provectusbio.com.For Media Inquiries:VisiRose, Inc.E: contact@visirose.comW: visirose.comContact:VisiRose, Inc.Dominic RodriguesActing Chief Executive OfficerE: rodrigues@visirose.comSOURCE: VisiRose Copyright 2024 ACN Newswire via SeaPRwire.com.
More
Provision of the First Template Function Adapted to the IFRS Sustainability Disclosure Standards in Japan (IFRS S1 and S2) on the Sustainable Finance Platform JCN Newswire

Provision of the First Template Function Adapted to the IFRS Sustainability Disclosure Standards in Japan (IFRS S1 and S2) on the Sustainable Finance Platform

TOKYO, Dec 10, 2024 - (JCN Newswire via SeaPRwire.com) - The Association for Promotion of Sustainable Finance Platform (AP-SFPF) and Hitachi, Ltd. (Hitachi) today announced that we will begin providing the first template feature adapted to the IFRS sustainability disclosure standards in Japan (IFRS S1 and S2*1) formulated by the International Sustainability Standards Board (ISSB), on the Sustainable Finance Platform - Engagement Support Service (SFP-ESS), a digital platform that promotes ESG investing by establishing seamless connections between asset management companies and listed companies.Specifically, Hitachi's SFP-ESS, developed under license from the IFRS Foundation, will be enhanced with a templatedesigned to facilitate reporting in accordance with IFRS S1 and S2 and the SASB Standards*2 (Templates). AP-SFPF will offer the Templates to asset management companies and listed companies in Japan as the service provider.By starting to provide the Templates, AP-SFPF and Hitachi will support listed companies in Japan in their disclosure of information in conformance with IFRS S1 and S2 and communication between listed companies and assetmanagement companies. This will enable global institutional investors to properly evaluate sustainability-conscious corporate activities in the ESG perspective and contribute to the enhancement of the companies' corporate value.AP-SFPF is a general incorporated association that was established to connect diverse stakeholders andpromote effective and efficient communication, solving issues and considering projects to contribute to the continued development of the ESG market. It was established in July 2023 by eight companies, which mainly include financial institutions: MS&AD Insurance Group Holdings, Inc., Sompo Japan Insurance Inc., Tokio Marine & Nichido Fire Insurance Co., Ltd., Nippon Life Insurance Company, Hitachi, Ltd., Mizuho Bank, Ltd., Sumitomo Mitsui Banking Corporation, and MUFG Bank, Ltd.Background of the start to adapt the SFP-ESS for IFRS S1 and S2Recently, investors' interest in companies' sustainability initiatives has been growing and companies are implementing sustainability initiatives and disclosing information about them. However, there are various disclosure standards in Japan and global. This has created an issue regarding disclosures. The people in charge of disclosing information,especially people at listed companies engaging in business globally, are not sure which standards to refer to and unable to determine investors' expectations regarding the disclosure of information, in addition to being short of resources. To solve this situation, the ISSB announced IFRS S1 and S2 in June 2023 as global baseline standards forthe disclosure of sustainability-related information.In Japan, the Sustainability Standards Board of Japan (SSBJ) is formulating the Japanese version of S1 and S2 (the SSBJ standards), which are made to comply with all of the requirements of IFRS S1 and S2, the standards fordisclosing sustainability-related informationin Japan. The finalized standards are planned to be published by March 2025. In addition, the Financial ServicesAgency made it mandatory to disclose sustainability-related information in securities reports in the fiscal year ended March 31, 2023. It is also considering the gradual application of the SSBJ standards to companies listed on the PrimeMarket starting in the fiscal year ending March 31, 2027. Therefore, listed companies are facing urgent tasks, such asthe collection of sustainability-related information and the development of a disclosure process in line with IFRS S1and S2, to prepare for the disclosure of information becoming mandatory in the future and to enhance their corporate value.In response, AP-SFPF exchanged opinions with more than 100 companies, including asset management companiesand listed companies, and began to offer a beta version of the SFP- ESS and verify its value in October 2023 to reduce the workload of the people at listed companies in charge of disclosing information and promote ESG investingin Japan. By using the Templates to adapt the SFP-ESS to IFRS S1 and S2, AP-SFPF and Hitachi will help listed companies smoothly disclose ESG information and contribute to improving their corporate value.Outline of SFP-ESSThe SFP-ESS is a two-sided platform on which asset management companies and listed companies making ESG investments are connected seamlessly to deepen their mutual understanding of each other. Asset managementcompanies present their needs regarding the ESG information it expected that listed companies disclose in line with theSASB*2 Standards. Listed companies refer to this registered information, which enables them to understand the needs of asset management companies and use the information when formulating their disclosure policies.Listed companies enter their data into the platform and send it, publishing it alongside comments by following the disclosure items in the Templates. This facilitates asset management companies' side-by-side comparison of listedcompanies as the viewers and also enables them to understand data, including the details.Features of the Templates adapted to IFRS S1 and S2Regarding IFRS S1 and S2, documents explaining the disclosure standards themselves, the IFRS Sustainability Disclosure Taxonomy*3, and support materials including a guide for the voluntary application of ISSB Standards havebeen published. However, Japanese documents are limited, and each company is left to decide how they will disclose the information they should disclose in their integrated reports and other reports. To support the practical tasks done by these listed companies, the Templates come with an input interface available in Japanese, so that digital data can be entered and saved on the platform in accordance with definitions in the taxonomy. Specifically, the Templates helplisted companies understand and respond to IFRS S1 and S2 using the following three features.1. Disclosure items classified into three categories (major categories, intermediate categories, and subcategories)The IFRS Sustainability Disclosure Taxonomy information is classified in detail into four core classifications (governance, strategy, risk management, and metrics and targets). However, the hierarchical structure differs from item to item. In response, a creative measure was devised to streamline data entry by the people in charge ofthe disclosure of information at listed companies by classifying the information into major categories,intermediate categories and subcategories visualizing the hierarchical structure of the information. This helps the people in charge of disclosing information at companies understand information collection based on the definitions in IFRS S1 and S2 without difficulty.2. Supplementary information from the IFRS Foundation regarding each disclosure item is provided when viewing the Templates.The IFRS Foundation, provides application guidance which companies may want to refer to when entering information into the Templates.3. Tables styles and options enabling an intuitive understanding of the information that needs to be disclosed are availableOptimal table styles are provided on an item-by-item basis to enable people to intuitively understand and enter the information required for each disclosure item. For example, there is an appropriate answer space for itemsthat are yes or no questions. In addition, for items which require that risks be described, there is a multiple-choice section about the type of risk (physical or transition) and the time frame (short, medium, or long term), in addition to the space for describing the risk. This prevent the omission of information or the provision of insufficient information.Future developmentMoving forward, AP-SFPF and Hitachi will broadly expand the SFP-ESS with the Templates to listed companies andtalk with multiple listed companies preparing to comply with IFRS S1 and S2 ahead of others. It will thus collect opinionsand requests regarding the improvement of the convenience of the Templates and develop the Templates so that we are more useful and adapted to IFRS S1 and S2.We will also work to functionally enhance the SFP-ESS in addition to developing the Templates. Specifically, they moveforward with consideration and development to provide service features which will be needed in the promotion ofthe disclosure of information, dialogue, and engagement between asset management companies and listedcompanies, such as a feature enabling asset management companies to register their information disclosure needs, and to release these features one by one. We also plan to incorporate the finalized SSBJ standards which will be published by the SSBJ by March 2025.Speaking at Director of Earned Revenue, IFRS Sustainability, Eli Reisman, said:“The IFRS Foundation welcomes Hitachi as a licensee of its standards. The IFRS Foundation encourages companiesvoluntarily applying IFRS S1 and IFRS S2, in addition to the progress being made towards regulatory adoption or other use of IFRS S1 and IFRS S2 happening in 25+ jurisdictions globally. In order to facilitate this corporate disclosure, it’s imperative that various services and tools integrate the ISSB standards to support this process."Yasuki Imai, Vice President and Executive Officer, Head of Digital Systems & Services APAC Business, and CEO of Financial Institutions Business Unit, Hitachi, Ltd, said:“In line with this approach to sustainability reporting, Hitachi and its only reseller of SFP-ESS, The Association forPromotion of Sustainable Finance Platform, aim to facilitate the application of IFRS S1, S2, and SASB standards and provide guidance on industry-specific disclosures through the SFP-ESS platform: SFP-ESS is a digital platformdesigned to support companies in their sustainability reporting efforts. This tool is intended to assist companies in navigating the reporting process, with the goal of enhancing the standardization and relevance of ESG reporting.”AP-SFPF member company, Managing Executive Officer, Group Chief Sustainability Officer (CSuO), MS&AD Insurance Group Holdings, Inc., Naomi Motojima said:“MS&AD Insurance Group Holdings, Inc. engages in investment, lending and insurance underwriting activities in consideration with ESG as a signatory to Principles for Sustainable Insurance (PSI) and the Principles for ResponsibleInvestment (PRI). We consider “Symbiosis with global environment ~Planetary Health~” as an important issue forMS&AD group, and we are working on realizing “Action on climate change” and “Improvement of sustainability of natural capital” comprehensively to enhance the resilience of society. We help to solve ESG issues including climate change through insurance underwriting, investment and lending, and of course we also work to reduce our own Greenhouse gas (GHG) emissions. We regard them as missions that we have as an insurance and financing serviceprovider. SFP-ESS is a platform that increases the mutual understanding of companies and financial institutions regarding ESG information disclosure. We hope that using the disclosure templates adapted to S1 and S2, which will be newly implemented, will facilitate the disclosure of information related to companies' ESG activities and lead to investors appropriately evaluating the companies. Further, from the standpoint of an investor, we find the developmentof a platform which enables users to compare the information disclosed by companies using a same index beneficial in the activities for the appropriate evaluation of the activities of the companies. Therefore, we welcome the release of the template feature.”*1 Disclosure standards announced by the IFRS Foundation in June 2023. The standards consist of IFRS S1 (General Requirements for Disclosure of Sustainability-related Financial Information) and IFRS S2 (Climate-related Disclosures).*2 The Sustainability Accounting Standards Board (SASB) Standards provide industry-specific ESG disclosure guidance focused on financial materiality. As of August 2022, the International Sustainability Standards Board (ISSB) of the IFRS Foundation assumed responsibility for the SASB Standards.*3 The IFRS Sustainability Disclosure Taxonomy is a framework for digitally tagging sustainability-related financial disclosures Its goal is to digitalize informationand facilitate investors' and stakeholders' comparison and assessment of companies' sustainability performanceSFP-ESS websitehttps://sfp-ess.org/en/service/About the Association for Promotion of Sustainable Finance Platform (AP-SFPF)The AP-SFPF was established in July 2023 to solve issues and consider projects, with financial institutions playing a leading role, to create new value and contribute to the continued development of the ESG market, eventually resultingin the sustainable development of society through the connection of various stakeholders to each other and the provision of a platform which will facilitate efficient and effective communication related to ESG issues.Member companies: MS&AD Insurance Group Holdings, Inc., Sompo Japan Insurance Inc., Tokio Marine & NichidoFire Insurance Co., Ltd., Nippon Life Insurance Company., Hitachi, Ltd., Mizuho Bank, Ltd., Sumitomo Mitsui Banking Corporation., MUFG Bank, Ltd.Representative: Yoshihiro Kanaoka, Representative Director Location: 1-6-1 Marunouchi,Chiyoda-ku, Tokyo 100-8220, Japan Corporate website: https://sfp-ess.org/en/About Hitachi, Ltd.Hitachi drives Social Innovation Business, creating a sustainable society through the use of data and technology. We solve customers' and society's challenges with Lumada solutions leveraging IT, OT (Operational Technology) and products. Hitachi operates under the 3 business sectors of “Digital Systems & Services” – supporting our customers’ digital transformation; “Green Energy & Mobility” – contributing to a decarbonized society through energy and railway systems, and “Connective Industries” – connecting products through digital technology to provide solutions in various industries. Driven by Digital, Green, and Innovation, we aim for growth through co-creation with our customers. The company’s revenues as 3 sectors for fiscal year 2023 (ended March 31, 2024) totaled 8,564.3 billion yen, with 573 consolidated subsidiaries and approximately 270,000 employees worldwide. For more information on Hitachi, please visit the company's website at www.hitachi.com. Copyright 2024 JCN Newswire via SeaPRwire.com.
More